Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials

• Principais autores: Seemal R. Desai (Autor), Linda Stein Gold (Autor), Michael C. Cameron (Autor), Alexandra Golant (Autor), G. Michael Lewitt (Autor), Matthew J. Bruno (Autor), George Martin (Autor), Philip M. Brown (Autor), David S. Rubenstein (Autor), Victoria Butners (Autor), Anna M. Tallman (Autor)
• Formato: Livro
• Publicado em: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Tapinarof cream 1% (VTAMA®; Dermavant Sciences, Inc.) is a non-steroidal, topical, aryl hydrocarbon receptor agonist approved by the US Food and Drug Administration (FDA) to treat plaque psoriasis in adults and under investigation for the treatment of psoriasis in children down to 2 years o...